- Published at
- by investing.com
mixed
mixed
NKGen Biotech avoids Nasdaq delisting with regained compliance By Investing.com
NKGen Biotech avoids Nasdaq delisting with regained compliance
News for Graf Acquisition Corp. IV (GFOR)
- Published at
- by seekingalpha.com
neutralneutralNKGen doses first patient in Phase 1/2a Alzheimer's study (NASDAQ:NKGN)
NKGen Biotech (NKGN) has dosed its first patient in a Phase 1/2a study for its cell therapy SNK01 in the treatment of moderate Alzheimer's disease. Read more here.- Published at
- by globenewswire.com
mixedmixedNKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease,...- Published at
- by seekingalpha.com
neutralneutralNewly public NKGen Biotech gets FDA okay for Alzheimer's therapy trials (NASDAQ:NKGN)
NKGen Biotech (NKGN) receives FDA clearance to begin clinical testing of its natural killer cell therapy for Alzheimer's disease. Read more here.- Published at
- by marketscreener.com
positivepositiveGraf Acquisition IV : Unaudited Condensed Consolidated Financial Statements - Form 8-K -October 05, 2023 at 05:16 pm EDT
Unaudited Condensed Consolidated Financial Statements Condensed Balance Sheets as of June 30, 2023 ...- Published at
- by seekingalpha.com
positivepositiveNKGen Biotech stock tumbles 30% following SPAC merger
NKGen Biotech shares closed 30% lower following its merger with Graf Acquisition Corp. IV.- Published at
- by globenewswire.com
positivepositiveNKGen Biotech, Inc. Announces Closing of Business Combination
Company to Commence Trading on Nasdaq under Ticker Symbol “NKGN” on Monday, October 2, 2023...- Published at
- by benzinga.com
positivepositiveNKGen Biotech, Inc. Announces Closing of Business Combination - NKGen Biotech (NASDAQ:NKGN)
SANTA ANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (- Published at
- by seekingalpha.com
positivepositiveSPAC Graf IV delays NKGen merger vote as it seeks additional financing (GFOR)
SPAC Graf IV (GFOR) has adjourned a special shareholders meeting to approve its planned merger with NKGen Biotech until Sept 20 as its seeks additional financing. Read more here.- Published at
- by marketscreener.com
positivepositiveGraf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
THE WOODLANDS, Texas, Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV , announced today that on September 8, 2023, it adjourned, without conducting any business, the special meeting of its...- Published at
- by globenewswire.com
mixedmixedNKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp....